London
· Delayed Price · Currency is GBP · Price in USD BioNTech SE Statistics
Total Valuation
BioNTech SE has a market cap or net worth of GBP 22.42 billion. The enterprise value is 7.51 billion.
| Market Cap | 22.42B |
| Enterprise Value | 7.51B |
Important Dates
The next estimated earnings date is Friday, March 21, 2025.
| Earnings Date | Mar 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.42% |
| Shares Change (QoQ) | +1.73% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 93.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 1.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -19.32 |
| EV / Sales | 2.73 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 7.41 |
Financial Position
The company has a current ratio of 7.33, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.33 |
| Quick Ratio | 7.10 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.20 |
| Interest Coverage | -24.21 |
Financial Efficiency
Return on equity (ROE) is -2.40% and return on invested capital (ROIC) is -1.40%.
| Return on Equity (ROE) | -2.40% |
| Return on Assets (ROA) | -1.23% |
| Return on Capital (ROIC) | -1.40% |
| Revenue Per Employee | 412,490 |
| Profits Per Employee | -63,350 |
| Employee Count | 6,133 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 1.33 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.02% in the last 52 weeks. The beta is 0.26, so BioNTech SE's price volatility has been lower than the market average.
| Beta (5Y) | 0.26 |
| 52-Week Price Change | +20.02% |
| 50-Day Moving Average | 114.92 |
| 200-Day Moving Average | 100.86 |
| Relative Strength Index (RSI) | 47.74 |
| Average Volume (20 Days) | 20,904 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.09 |
Income Statement
In the last 12 months, BioNTech SE had revenue of GBP 2.53 billion and -388.53 million in losses. Loss per share was -1.62.
| Revenue | 2.53B |
| Gross Profit | 2.13B |
| Operating Income | -366.73M |
| Pretax Income | -262.71M |
| Net Income | -388.53M |
| EBITDA | -228.42M |
| EBIT | -366.73M |
| Loss Per Share | -1.62 |
Balance Sheet
The company has 13.90 billion in cash and 202.79 million in debt, giving a net cash position of 13.70 billion.
| Cash & Cash Equivalents | 13.90B |
| Total Debt | 202.79M |
| Net Cash | 13.70B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 15.91B |
| Book Value Per Share | 66.35 |
| Working Capital | 13.28B |
Cash Flow
In the last 12 months, operating cash flow was 1.27 billion and capital expenditures -252.64 million, giving a free cash flow of 1.01 billion.
| Operating Cash Flow | 1.27B |
| Capital Expenditures | -252.64M |
| Free Cash Flow | 1.01B |
| FCF Per Share | n/a |
Margins
Gross margin is 84.31%, with operating and profit margins of -14.50% and -15.36%.
| Gross Margin | 84.31% |
| Operating Margin | -14.50% |
| Pretax Margin | -10.38% |
| Profit Margin | -15.36% |
| EBITDA Margin | -9.03% |
| EBIT Margin | -14.50% |
| FCF Margin | 40.07% |
Dividends & Yields
BioNTech SE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.42% |
| Shareholder Yield | 0.42% |
| Earnings Yield | -1.73% |
| FCF Yield | 4.52% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNTech SE has an Altman Z-Score of 5.93.
| Altman Z-Score | 5.93 |
| Piotroski F-Score | n/a |